artemisinin

artemisinin is a sesquiterpene lactone containing a peroxide bridge, which is responsible for its potent antimalarial activity. It is a secondary metabolite produced by the sweet wormwood plant, Artemisia annua, and serves as the foundation for the most effective contemporary treatments for Plasmodium falciparum malaria. The discovery of its therapeutic properties, stemming from traditional Chinese medicine, marked a pivotal breakthrough in tropical medicine and earned Tu Youyou a share of the 2015 Nobel Prize in Physiology or Medicine. Its unique mechanism, involving the generation of free radicals upon activation by iron, sets it apart from other antimalarial classes like quinine and chloroquine.

History and discovery

The use of Artemisia annua for treating fevers was documented in ancient Chinese medical texts, such as the Huangdi Neijing and the Zhouhou Beiji Fang by Ge Hong. Modern research into the plant was initiated in 1967 under Project 523, a secret military program of the People's Republic of China aimed at finding new antimalarials during the Vietnam War. In 1972, a team led by pharmacologist Tu Youyou successfully isolated the active compound, initially referred to as Qinghaosu. This discovery was first publicly disclosed in 1977, and subsequent international validation by organizations like the World Health Organization confirmed its efficacy against drug-resistant strains of Plasmodium falciparum.

Chemical structure and properties

Artemisinin is a colorless, crystalline solid with a complex structure featuring a sesquiterpene skeleton and a distinctive 1,2,4-trioxane ring system containing an endoperoxide bridge. This peroxide group (–O–O–) is the pharmacophore essential for its biological activity. The molecule's stereochemistry includes several chiral centers, making its synthesis challenging. Its poor solubility in water and oil historically posed formulation difficulties, leading to the development of more soluble semi-synthetic derivatives like artemether and artesunate.

Biosynthesis and production

In Artemisia annua, artemisinin is biosynthesized in the glandular trichomes of its leaves and flowers. The pathway begins with the conversion of isopentenyl pyrophosphate and dimethylallyl pyrophosphate into farnesyl pyrophosphate, which undergoes cyclization to form amorpha-4,11-diene, a key intermediate catalyzed by the enzyme amorpha-4,11-diene synthase. Subsequent oxidation steps, involving a cytochrome P450 monooxygenase (CYP71AV1), yield artemisinic acid, which is then converted to artemisinin. While plant extraction remains a primary source, efforts to produce it via engineered Saccharomyces cerevisiae or Nicotiana benthamiana are ongoing to increase global supply.

Mechanism of action

The antimalarial action is triggered when the parasite, residing within the host's red blood cells, digests hemoglobin, releasing heme and free ferrous iron (Fe²⁺). This iron cleaves the endoperoxide bridge in artemisinin, generating highly reactive oxygen-centered free radicals and carbon-centered radicals. These radicals alkylate and damage critical parasite proteins, including the sarco/endoplasmic reticulum calcium ATPase (SERCA) ortholog PfATP6, and cause extensive oxidative stress, leading to rapid parasite death during the early trophozoite stage of its intraerythrocytic life cycle.

Medical uses and resistance

Artemisinin and its derivatives are the cornerstone of first-line treatments for uncomplicated Plasmodium falciparum malaria, always administered in combination with a partner drug as Artemisinin-based combination therapy (ACT) to delay resistance. They are also critical for treating severe malaria, where intravenous artesunate is the recommended therapy. Partial resistance, characterized by delayed parasite clearance, has emerged in the Greater Mekong Subregion, notably in Cambodia, Thailand, and Myanmar, and is associated with mutations in the Plasmodium falciparum Kelch13 gene. Monitoring by the World Health Organization and institutions like the Wellcome Trust is crucial for containment.

Research and derivatives

Extensive research has produced semi-synthetic derivatives with improved pharmacokinetics. Key compounds include artemether (lipid-soluble, used in co-formulations with lumefantrine), artesunate (water-soluble, for injection), and dihydroartemisinin, the active metabolite of most derivatives. Beyond malaria, investigations explore potential anticancer, antiviral, and anti-inflammatory properties. Fully synthetic peroxides, such as arterolane and artefenomel, developed through collaborations like the Medicines for Malaria Venture, aim to provide next-generation agents with simplified manufacturing and activity against resistant strains.